Anti-inflammatory drugs and risk of Parkinson disease
A meta-analysis
Abstract
Background/Objective: Anti-inflammatory drugs may prevent Parkinson disease (PD) by inhibiting a putative underlying neuroinflammatory process. We tested the hypothesis that anti-inflammatory drugs reduce PD incidence and that there are differential effects by type of anti-inflammatory, duration of use, or intensity of use.
Methods: MEDLINE and EMBASE were searched for studies that reported risk of PD associated with anti-inflammatory medications. Random-effects meta-analyses were used to pool results across studies for each type of anti-inflammatory drug. Stratified meta-analyses were used to assess duration- and intensity-response.
Results: Seven studies were identified that met the inclusion criteria, all of which reported associations between nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) and PD, 6 of which reported on aspirin, and 2 of which reported on acetaminophen. Overall, a 15% reduction in PD incidence was observed among users of nonaspirin NSAIDS (relative risk [RR] 0.85, 95% confidence interval [CI] 0.77–0.94), with a similar effect observed for ibuprofen use. The protective effect of nonaspirin NSAIDs was more pronounced among regular users (RR 0.71, 95% CI 0.58–0.89) and long-term users (RR 0.79, 95% CI 0.59–1.07). No protective effect was observed for aspirin (RR 1.08, 95% CI 0.92–1.27) or acetaminophen (RR 1.06, 95% CI 0.87–1.30). Sensitivity analyses found results to be robust.
Conclusions: There may be a protective effect of nonaspirin nonsteroidal anti-inflammatory drug use on risk of Parkinson disease (PD) consistent with a possible neuroinflammatory pathway in PD pathogenesis.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
REFERENCES
1.
Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 2008;70(pt 2):1423–1430.
2.
Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384–386.
3.
Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009;8:382–397.
4.
Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003;53(suppl 3):S49–S58.
5.
Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001;39:167–174.
6.
Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005;58:963–967.
7.
Chen H, Zhang SM, Hernán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059–1064.
8.
Ton TG, Heckbert SR, Longstreth WT Jr, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006;21:964–969.
9.
Hernán MA, Logroscino G, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006;66:1097–1099.
10.
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–2012.
11.
Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson disease. Neurology 2009;72:578–579.
12.
Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Health Research Institute. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed March 4, 2009.
13.
Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 2008;300:1674–1684.
14.
Aziz O, Constantinides V, Tekkis PP, et al. Laparoscopic versus open surgery for rectal cancer: a meta-analysis. Ann Surg Oncol 2006;13:413–424.
15.
Gagne JJ, Griesdale DE, Schneeweiss S. Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. Pharmacoepidemiol Drug Saf 2009;18:259–268.
16.
Stead LG, Gilmore RM, Bellolio MF, Rabinstein AA, Decker WW. Percutaneous clot removal devices in acute ischemic stroke: a systematic review and meta-analysis. Arch Neurol 2008;65:1024–1030.
17.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
18.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.
19.
Hancock DB, Martin ER, Vance JM, Scott WK. Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease. Neurogenetics 2008;9:249–262.
20.
Etminan M, Suissa S. NSAID use and the risk of Parkinson's disease. Curr Drug Saf 2006;1:223–225.
21.
Etminan M, Carleton BC, Samii A. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 2008;15:576–577.
22.
Bornebroek M, de Lau LM, Haag MD, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 2007;28:193–196.
23.
Hancock DB, Martin ER, Stajich JM, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007;64:576–580.
24.
Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 2006;67:494–496.
25.
Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007;69:1836–1842.
26.
Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 2008;23:88–95.
27.
Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168–175.
28.
Wahner AD, Sinsheimer JS, Bronstein JM, Ritz B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol 2007;64:836–840.
29.
Håkansson A, Westberg L, Nisson S, et al. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am J Med Genet B Neuropsychiat Genet 2005;133B:88–92.
30.
Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007;205:295–312.
31.
Asanuma M, Miyazaki I. Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease? Exp Neurol 2007;206:172–178.
32.
Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006;79:9–19.
33.
Hernán MA, Alonso A, Logroscino G. Cigarette smoking and dementia: potential selection bias in the elderly. Epidemiology 2008;19:448–450.
34.
Chandra NC, Ziegelstein RC, Rogers WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch Intern Med 1998;158:981–988.
35.
Gan SC, Beaver SK, Houck PM, MacLehose RF, Lawson HW, Chan L. Treatment of acute myocardial infarction and 30-day mortality among women and men. N Engl J Med 2000;343:8–15.
36.
Blomkalns AL, Chen AY, Hochman JS, et al; CRUSADE Investigators. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005;45:832–837.
37.
Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009;26:769–779.
38.
Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. 15-Epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 2004;200:69–78.
39.
Liu B, Gao HM, Hong JS. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 2003;111:1065–1073.
Information & Authors
Information
Published In
Copyright
© 2010.
Publication History
Published online: March 22, 2010
Published in print: March 23, 2010
Notes
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Peripheral blood inflammatory cytokines in prodromal and overt α-synucleinopathies: a review of current evidence, encephalitis, 3, 3, (81-86), (2023).https://doi.org/10.47936/encephalitis.2023.00031
- Naphthoquinones as a Promising Class of Compounds for Facing the Challenge of Parkinson’s Disease, Pharmaceuticals, 16, 11, (1577), (2023).https://doi.org/10.3390/ph16111577
- Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson’s Disease, International Journal of Molecular Sciences, 24, 15, (12339), (2023).https://doi.org/10.3390/ijms241512339
- C1q and central nervous system disorders, Frontiers in Immunology, 14, (2023).https://doi.org/10.3389/fimmu.2023.1145649
- The association between Parkinson’s disease and autoimmune diseases: A systematic review and meta-analysis, Frontiers in Immunology, 14, (2023).https://doi.org/10.3389/fimmu.2023.1103053
- Prognostic significance of peripheral neutrophils and lymphocytes in early untreated Parkinson’s disease: an 8-year follow-up study, Journal of Neurology, Neurosurgery & Psychiatry, 94, 12, (1040-1046), (2023).https://doi.org/10.1136/jnnp-2022-330394
- Immunity impacts cognitive deficits across neurological disorders, Journal of Neurochemistry, (2023).https://doi.org/10.1111/jnc.15999
- Transcriptional and epigenetic decoding of the microglial aging process, Nature Aging, 3, 10, (1288-1311), (2023).https://doi.org/10.1038/s43587-023-00479-x
- Low-moderate dose whole-brain γ-ray irradiation modulates the expressions of glial fibrillary acidic protein and intercellular adhesion molecule-1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine–induced Parkinson’s disease mouse model, Neurobiology of Aging, 132, (175-184), (2023).https://doi.org/10.1016/j.neurobiolaging.2023.06.015
- The complex role of inflammation and gliotransmitters in Parkinson's disease, Neurobiology of Disease, 176, (105940), (2023).https://doi.org/10.1016/j.nbd.2022.105940
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.